Anthony Buisson
Anthony Buisson, MD, PhD is an expert in Gastroenterology at Centre Hospitalier Universitaire de Clermont-Ferrand (France). As of October 2026, ScienceLeadR ranks Anthony Buisson in the top 1% of experts worldwide for Crohn Disease, Inflammatory Bowel Diseases and Gastroenteritis. Anthony Buisson has authored 481 publications, the most recent in 2026, and is an investigator in 44 clinical trials, 27 of them ongoing. SLR score: 2,515 (community average: 125). How the SLR is computed.
LeadR Profile
Gastroenterology
Subspecialties: Hepatology - Public Health - Pharmacy
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2012 - 2026
Number : 481
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Fecal microbiota transplantation for the decolonization of mucosal adherent-invasive Escherichia coli in Crohn's disease: an open-label pilot study. PMID 42860401 — escherichia, pilot projects, pilots, fecal microbiota transplantation, crohn disease, drug-related side effects and adverse reactions, escherichia coli, transplantation, microbiota | Nat Commun | 2026 | 0 |
| Acceptability and tolerability of risankizumab maintenance therapy administered via on-body injector in patients with Crohn's disease: Results of the ACCEPT-OBI study. PMID 42729518 — injections, crohn disease, maintenance, drug-related side effects and adverse reactions, inflammatory bowel diseases, therapeutics, infusions, intravenous | Ther Adv Gastroenterol | 2026 | 0 |
| Subcutaneous infliximab in the treatment of patients with perianal fistulizing Crohn's disease: current evidence and emerging roles. PMID 42488031 — fistula, safety, crohn disease, therapeutics, infliximab | Ther Adv Gastroenterol | 2026 | 0 |
| Methotrexate for inflammatory bowel disease: the MICI-METHO multicenter retrospective cohort study. PMID 42484615 — safety, cohort studies, drug-related side effects and adverse reactions, inflammatory bowel diseases, therapeutics, methotrexate | J Crohns Colitis | 2026 | 0 |
| Association of bowel urgency, disease activity and disability in patients with inflammatory Bowel Disease: A cross-sectional study from the GETAID. PMID 42250793 — cross-sectional studies, pain, inflammatory bowel diseases, fatigue, work, therapeutics, colitis, ulcerative, abdominal pain | Clin Res Hepatol Gastroenterol | 2026 | 0 |
Clinical Studies 44
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Main Topics
Cohort/Consortium Investigators 7
Ongoing Clinical Trials
27 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| A Study to Assess the Efficacy Safety and what the body does to RO7837195 in Participants with Moderately to Severely Active Ulcerative Colitis 2025-520690-39-00 — colitis, safety, therapeutics, colitis, ulcerative, pharmacokinetics | Phase 2 | Not yet recruiting | 2025 |
| Crohn s Head to Head Assessing Risankizumab Versus Guselkumab for One Year 2025-521590-13-00 — safety, crohn disease, therapeutics, head | Phase 3 | Recruiting | 2026 |
| Efficacy and Safety of Icotrokinra in Adult and Adolescent Participants with Moderately to Severely Active Ulcerative Colitis 2025-521381-10-00 — colitis, safety, maintenance, adolescent, therapeutics, colitis, ulcerative | Phase 3 | Recruiting | 2025 |
| A Continuation Study of TAK 279 in Adults With Ulcerative Colitis (UC) and Crohn s Disease (CD) 2024-518914-18-00 — colitis, safety, crohn disease, therapeutics, colitis, ulcerative | Phase 2 | Not yet recruiting | 2025 |
| Safety and Efficacy of a STOPping Strategy Versus Classical Maintenance Dose of JAK Inhibitors in Deep Remission Patients With Ulcerative Colitis NCT07718529 — colitis, safety, maintenance, therapeutics, janus kinase inhibitors, colitis, ulcerative | Phase 4 | Not yet recruiting | 2027 |
LeadR Networks
Main global connection map